tbuckley/cabot-search huggingface dataset:
322P The utility of tumour markers in detecting relapses in testicular seminoma: Largest experience from a comprehensive cancer centre in India
Authors: D. Samaddar, A. Dhanawat, B. Jadhav, A. Tiwari, K. Jobanputra, M.J. Shah, N.S. Menon, P. Maitre, M. Pal, A. Arora, A. Ringe, A. Agrawal, S. Menon, G. Prakash, V. Murthy, V. Noronha, K. Prabhash, A.P. Joshi
Journal: Annals of Oncology (2024)
202P Hepatic arterial infusion tislelizumab and chemotherapy plus DEB-TACE in combination with lenvatinib for first-line treatment of unresectable HCC: A prospective, single arm, phase II study (HAITC study)
Authors: H. Yu, Y. Xu, W. Xing, Z. Guo, C. Liu, W. Gao, Y. Xueling, W. Zhang, Y. Li
Journal: Annals of Oncology (2024)
99P Analysis of prognostic factors on trifluridine-tipiracil plus bevacizumab treatment in metastatic colorectal cancer: A retrospective real-world analysis
Authors: M. Onishi, T. Hirose, H. Shoji, N.T. Okita, H. Hirano, A. Takashima, K. Kato
Journal: Annals of Oncology (2024)
289P Difference in oncological efficacy between subsequent anti-PD-L1 and anti-PD-1 inhibitors following first-line platinum-based chemotherapy for patients with advanced urothelial carcinoma
Authors: R. Kawashima, M. Miyake, N. Nishimura, K. Sakamoto, T. Miyamoto, Y. Iemura, K. Iida, M. Tanaka, K. Fujimoto
Journal: Annals of Oncology (2024)
118TiP Neoadjuvant CAPOX plus SCT510 (bevacizumab biosimilar) and finotonlimab in high-risk resectable colorectal liver metastases (CRLM): A multicenter, phase II study
Authors: W. Qiu, W. Qi, J. Lv, S. Wang, J. Guo, J. Song, S. Zhao
Journal: Annals of Oncology (2024)
173P Gastric adenocarcinoma: Does the location matter? A retrospective study from a single oncology center
Authors: A.M. Abdalhadi, M. Sir Elkhatim, S. Abdelrahim, N.E. Omar, S. Abdo, A. Jama, R. Anil, W.M.M. Abdalla, A. Akram, M. Mostafa, K.I. Rasul, A. Shablak
Journal: Annals of Oncology (2024)
270O Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone in Asian patients with previously untreated unresectable or metastatic urothelial carcinoma (u/mUC) from CheckMate 901
Authors: Y. Tomita, D. Ye, A. Fujii, N. Takeuchi
Journal: Annals of Oncology (2024)
LBA1 Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04)
Authors: C. Yoo, H-D. Kim, H.J. Chon, S.J. Sym, M. Kim, J.H. Kang, B-Y. Ryoo, C-K. Lee, J. Hong, H. Ryu, W.K. Bae, H. Kim, H. Kim, J.W. Kim, T-Y. Kim
Journal: Annals of Oncology (2024)
128MO Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma
Authors: S.Y. Rha, A. Kawazoe, Y. Bai, J. Xu, S. Lonardi, J-P. Metges, P.E. Yanez Weber, L.S. Wyrwicz, L. Shen, Y.V. Ostapenko, M. Bilici, H.C. Chung, K. Shitara, M. Mahave, E. van Cutsem, J. Tabernero, L. Xu, K.P. Sharan, P. Bhagia, Y.Y. Janjigian
Journal: Annals of Oncology (2024)
360P Real-world treatment and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): REMPRO-Middle East and Africa (MEA)
Authors: G. El Husseiny, A. Nowier, B. Basulaiman, R. Ghali, H. Farag, A. Aboutaleb, V. Rajadhyaksha, S.H. Tirmazy, B. Sahin
Journal: Annals of Oncology (2024)
288P The role of organ-specific response to enfortumab vedotin on survival in advanced urothelial carcinoma patients: A Japanese multicenter retrospective study
Authors: N. Hayakawa, G. Kaneko, D. Ikarashi, Y. Endo, Y. Sakura, R. Yamashita, W. Obara, Y. Kondo, E. Kikuchi
Journal: Annals of Oncology (2024)
223P Hepatic artery infusion chemotherapy (HAIC) combined with camrelizumab and apatinib as conversion therapy for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial
Authors: X. Zhou, H. Zhu, H. Gao, Z. Niu, M. Liu, H. Wang, X. Kong, C. Ma, F. Yang, Y. Hao, S. Zhang, J. Lu
Journal: Annals of Oncology (2024)
382P Landscape of genomic alterations in chemoradiation resistant cervical cancer patients using whole-genome sequencing
Authors: P. Kumar, R. Chauhan, V. Trivedi, E. Dhawale, J. Sambath, I.A. George, S.S. Manda, R.S. Kommu, M. Singh, R. Venkataramanan
Journal: Annals of Oncology (2024)
201P Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: Updated efficacy and safety results from the phase II NeoLEAP-HCC study
Authors: K. Wang, N. Yang, H. Xue, Y-C. Yang, H. Sun, X. Zhu, Y-J. Chen, M. Kuang, F. Ye, S. Shen, C. Huang, Y. Shen, Y-F. Sun, F. Xue, J. Liu, S. Bai, Z. Yang, J. Zhou, J. Fan
Journal: Annals of Oncology (2024)
120TiP Neoadjuvant short-course radiotherapy combined with chemotherapy and cadonilimab for patients with locally advanced rectal cancer: A prospective, single-arm phase II trial
Authors: J. Rao, Z. Chen, Z. Wang, S. Xu, J. Peng, S. Niu, Y. Bao, X. Song, S. Cai, C. Chen
Journal: Annals of Oncology (2024)
263TiP TroFuse-015: A phase III study of trophoblast antigen 2 (TROP2)–directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Authors: K. Shitara, Z.A. Wainberg, E. van Cutsem, Y.Y. Janjigian, R-H. Xu, D-Y. Oh, J. Xu, S. Wu, S. Bhaumik, P. Bhagia, J. Tabernero
Journal: Annals of Oncology (2024)
126O Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
Authors: T. Yau, P.R. Galle, T. Decaens, B. Sangro, S. Qin, J-W. Park, M. Ikeda, D.W.M. Tai, C-F. Chiu, H.J. Chon, Y-K. Kang, A. Hiraoka, Y-H. Huang, T-Y. Lee, K. Numata, T. Yamashita, T. Ogata, J. Hreiki, Y. Lu, M. Kudo
Journal: Annals of Oncology (2024)
147P Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study
Authors: H-W. Sim, S-A. McLachlan, A. Dean, T.J. Price, M. Eastgate, L. Rimassa, T. Macarulla Mercade, D. Malka, H. Gharbi, R. Robert, A. Sullivan, A. Vogel
Journal: Annals of Oncology (2024)
349P Predictive gene signature in primary prostate cancer associated with regional lymph-node metastasis using both mRNA and miRNA profiling
Authors: D.S. Hoon, K.K. Chong, Y. Koh, S. Kim, E. Ziarnik, R.I. Ramos, G. Jimenez, D.L. Krasne, W.M. Allen, T.G. Wilson, M.A. Bustos
Journal: Annals of Oncology (2024)
91P Clinicopathological and molecular features of claudin-18 isoform 2 in pathological stage I–III colorectal cancer
Authors: S. Takamizawa, H. Hirano, A. Takashima, H. Shoji, T. Hirose, N.T. Okita, K. Shiraish, S. Sekine, Y. Takamizawa, Y. Kanemitsu, K. Kato
Journal: Annals of Oncology (2024)
367P Patients health-related quality of life in men with prostate cancer treated by enzalutamide: A systematic review
Authors: M.Z. Sabran, M.G. Wibisono, M.H.H. Wibisono, C-Y. Li, S-Y. Liao, J.J. Wibisono, A. Kurniawan, I. Huang
Journal: Annals of Oncology (2024)
82P Results from FRONT study: A multicenter, randomized, open-label clinical trial of fruquintinib as maintenance therapy after 1L treatment in metastatic colorectal cancer (mCRC)
Authors: X. Xu, Y. Yu, Q. Liu, Y. Wang, Y. Cui, W. Li, Q. Li, Y. Feng, L. Liang, S. Yu, Z. Lv, T. Liu
Journal: Annals of Oncology (2024)
86P Impact of renal impairment on chemotherapy-induced neutropenia in patients who are treated with trifluridine/thymidine phosphorylase inhibitor + bevacizumab for metastatic colorectal cancer
Authors: M. Shibutani, H. Tanda, H. Kasashima, T. Fukuoka, S. Kashiwagi, K. Maeda
Journal: Annals of Oncology (2024)
368P Causal relationships between dietary habits and prostate cancer: A two-sample Mendelian randomization study
Authors: H. Zeng, Q. Zhu, J. Dai, J. Guo, Q. Wang, N. Xu, Y. Xie, J. Chen, J. Zhao, G. Sun, H. Zeng, P. Shen
Journal: Annals of Oncology (2024)
345P Patient-reported outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Results from the China ARCHES trial
Authors: D. Ye, Y. Chang, Y. Li, G. Zeng, H. Guo, Z. Hu, X. Zhang, D. He, Z. He, D. Zhang, X. Lu, H. Kadeerbai, Y. Liu, F. Zhou
Journal: Annals of Oncology (2024)
163P A comparison of the dietary intake after surgery in gastric cancer patients between laparoscopic-assisted and conventional gastrectomy
Authors: J. Morita, M. Tanabe, Y. Nakayama, K. Kanematsu, S. Nagasawa, T. Yamada, Y. Maezawa, K. Kazama, K. Numata, T. Aoyama, N. Yukawa, T. Ogata, A. Saito, T. Oshima
Journal: Annals of Oncology (2024)
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Authors: Q. Au, H. Nunns, E. Parnell, K. Gallagher, E. Leones, F. Sahafi, V. Chizhevsky
Journal: Annals of Oncology (2024)
LBA2 Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up of the East Asian subgroup of the randomized phase III LITESPARK-005 trial
Authors: J-L. Lee, S.H. Park, T. Kato, T. Saika, N. Masumori, M. Oya, K. Nishimoto, H. Fujimoto, M. Eto, T. Kishida, H.J. Lee, Y-L. Su, Y. Miura, N. Matsubara, H. Kitamura, A.C.K. Cheng, A. Xing, R. Perini, D. Vickery, B.I. Rini
Journal: Annals of Oncology (2024)
352P Unveiling the potential of [-2]pro PSA-related index in TZ prostate cancer diagnosis
Authors: Y. Toyama, G. Kimura, J. Akatsuka, Y. Endo, H. Takeda, K. Obayashi, H. Mikami, H. Hasegawa, R. Funato, M. Taniuchi, R. Takahashi, Y. Kondo
Journal: Annals of Oncology (2024)
261TiP Randomized, open-label, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA/m) biliary tract cancer (BTC): DESTINY-BTC01
Authors: M. Ikeda, M. Kuang, D-Y. Oh, G. Cohen, S. Raoufmoghaddam, M. Winter, M. Javle
Journal: Annals of Oncology (2024)
187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies
Authors: Z. Lu, J. Zhao, Z. Wang, D. Qian, Z. Yang, N. Li, J. Wang, S. Yuan, Y. Wang, S. Li, Z. Yang, F. Ran, Y. Ji, S. Zhu, Y. Zhang, C. Wang, L. Wan, None J. li, G. Sun, L. Shen
Journal: Annals of Oncology (2024)
373O First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study
Authors: N. Liu, Z. Yang, D. Tang, H. Lou, K. Zhang, H. Cao, D. Zou, X. Zhang, S. Xue, X. Kang, D. Wang
Journal: Annals of Oncology (2024)
79P The role of regorafenib for metastatic colorectal cancer in the new era of later-line treatment: Results of the OSERO study
Authors: T. Matsumoto, T. Kawakami, T. Hamano, T. Masuishi, A. Chida, S. Mitani, A. Ishiguro, T. Ando, K. Sawada, K. Harada, N. Takahashi, S. Boku, T. Kashiwada, T. Esaki, M. Yagisawa, K. Sugiyama, K. Yamamoto, S. Yuki, K. Yamazaki, E. Oki
Journal: Annals of Oncology (2024)
273MO DURANCE: A phase Ib/II study to assess the safety and activity of durvalumab (MEDI4736) in combination with S-488210/S-488211 vaccine in non-muscle invasive bladder cancer
Authors: G. Leone, A. Shokri, B.E. Szabados, V. Khoo, S. Crabb, D. Enting, T.B. Powles, C.H.H. Ottensmeier, S. Quezada, R. Begum, R. Musleh, M. Duggan, M.K. Rashid, M. Linch
Journal: Annals of Oncology (2024)
160P Peritoneal niche evolution and micro-environmental remodeling in gastric cancer peritoneal metastasis
Authors: J.J. Zhao, J. Ong, D. Chia, M.C.H. Ng, R.J. Walsh, Q.X. Tan, J.W-S. Tan, H. Ma, X. Ong, S.T. Tay, W.P. Yong, J.B.Y. So, P. Tan, R. Sundar
Journal: Annals of Oncology (2024)
208P Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo+bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)–unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria
Authors: T. Yamashita, K. Ueshima, K. Tsuchiya, N. Kato, S. Shimose, K. Numata, Y. Kodama, K. Ohkawa, T. Kuzuya, M. Ikeda, Y. Kooka, H. Aikata, A. Hiraoka, M. Moriguchi, K. Fujiwara, G. Suda, S. Mochida, S. Ogasawara, K. Yamamoto, M. Kudo
Journal: Annals of Oncology (2024)
131MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
Authors: K. Kato, R-H. Xu, D-Y. Oh, Y. Bai, J. Shi, K-W. Lee, H. Hirano, H. Xu, T. Sheng, G. Barnes
Journal: Annals of Oncology (2024)
148P Real-world data of advanced gallbladder cancers in Eastern India: A single institutional analysis of 100 patients
Authors: S.K. Mishra, D. Muduly, B. Pattnayak, S.M. Ali, B. Rout, K. Agarwal, P. Mishra, B. Sahoo, M. Panigrahy, I. Vanidassane, H.K. Nayak, S. Gupta, D. Das, K. Ygl, R. Chandra Teja
Journal: Annals of Oncology (2024)
259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study
Authors: J. Xu, K. Jiang, H. Lu, X. Gong, H. Li, Y. Wu, L. Chen, W. Liu, D. Wu, J. Du, L. Sun, Y. Zhao, E. Dai, H. An, Y. Liu, X. Wang, Q. Liu, X. Yu
Journal: Annals of Oncology (2024)
258P Current trends in treatment regimens and overall survival for patients with advanced pancreatic cancer in a real-world setting
Authors: H. Imaoka, M. Sasaki, K. Watanabe, T. Satake, T. Shibuki, K. Inoue, T. Taira, S. Yamaguchi, G. Igarashi, S. Mitsunaga, M. Ikeda
Journal: Annals of Oncology (2024)
271O Interim analysis (IA) of SPADE: A prospective, real-world study of avelumab first-line maintenance (1LM) treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Asia-Pacific (APAC) region
Authors: S.H. Park, J. Jo, M. Kim, S.J. Shin, I-H. Kim, Y-H. Huang, Y-C. Tsai, N. Oliveira, S.J. Rajappa, Y. Wang, J. Hoffman, P.J. Su
Journal: Annals of Oncology (2024)
103P Characteristics of colon cancer in the comprehensive cancer center and overall survival of young versus old patients: Single institute experience from 2015 -2021
Authors: H.A. Alghanmi, E. Tashkandi, A.H. Almatari, M.H. Elsafty, A. Refaat, D.K. Mohorjy, K.A. Naghi
Journal: Annals of Oncology (2024)
77P Efficacy and safety of iparomlimab and tuvonralimab (QL1706) in untreated metastatic colorectal cancer (mCRC)
Authors: J. Li, Y. Bai, Y. Li, C. Jin, Y. Jin, Z. Niu, C. Jiang, Y. Gao, Y. Xu, D. Yang, Y. Lin, W. Su, P. Wang, W. Wang, Z. Wang, M. Si, L. Li, X. Kang
Journal: Annals of Oncology (2024)
205P Transarterial chemoembolization with immune checkpoint inhibitors and anti-VEGF antibody/tyrosine kinase inhibitors as first-line treatment for intermediate-stage hepatocellular carcinoma (CHANCE2202): A target trial emulation study
Authors: J-J. Chen, Z-C. Jin, B-Y. Zhong, H. Zhu, G. Teng
Journal: Annals of Oncology (2024)
241P Biliary tract cancers from Western India: A study depicting demographic trends, presentation of molecular landscape and survival outcomes
Authors: U.D. Maheshwari, K.N. Jobanputra, D. Morzaria, D.A. Joshi, P. Kalaskar, V. Maniar, K. Joshi, K. Chaudhari, S. Sheth, R. Dave, T. Sethjiwala, P. Devde, P. Khandare, S. Jagiasi
Journal: Annals of Oncology (2024)
265TiP Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U06 substudy 06B
Authors: J-M. Sun, T. Doi, P.C. Enzinger, M.A. Shah, A. Adenis, J. Wu, K.P. Sharan, P. Bhagia, K. Kato, L. Shen
Journal: Annals of Oncology (2024)
149P Positivity rates of FGFR2 fusion gene or rearrangement and genetic profiling in Asian Cholangiocarcinoma
Authors: Y. Maruki, Y. Yatabe, M. Chiharu, A. Sookprasert, C. Akewanlop, M-H. Chen, E. Sirachainan, V.T. Dao, R. Abdul Malik, C. Charoentum, S.H. Hwoei Fen, S. Yusak, T-H. Liu, R. Rangasamy, P. Sunpaweravong, P-J. Voon, N. Abu Bakar, H.S. Okuma, K. Nakamura, T. Okusaka
Journal: Annals of Oncology (2024)
83P Efficacy and safety of cetuximab plus raltitrexed as first-line maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): An interim analysis of a multi-center phase II trial
Authors: S. Li, L. Zhu, M. Zhao, J. Xu, H. Jiang, X. Zhong, S. Xu, H. Shen, L. Qiao
Journal: Annals of Oncology (2024)
336MO A phase II single-arm, open-label trial of pamiparib in metastatic castration-resistant prostate cancer (mCRPC) patients with deleterious germline or somatic BRCA1/2 alterations or homologous recombination deficiency (HRD): Interim analysis of efficacy and safety results
Authors: D. Zhao, J. Zhao, F. Zhou, Y. Li, J. Wang
Journal: Annals of Oncology (2024)
164P Efficacy and safety of anlotinib plus toripalimab as first-line regimen in advanced gastric cancer patients with performance status 2 (PS 2): An open-label, single arm, phase II trial
Authors: K. Liu, B. Qin, S. Chen, X. Zhong, X. Duan, Y. Wu, Y. Ling, L. Sun, D. Shi, X. Jiao, Y. Zang
Journal: Annals of Oncology (2024)
74MO mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody in locally advanced MSS CRC (BASKETⅡ): A prospective, single-arm, open-label, phase II study
Authors: J. Huang, W. He, Y. Zhao, F. He, Z. Liu, F. Pei, Q. Yao
Journal: Annals of Oncology (2024)
75P Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study
Authors: Z. Wang, B. Qin, C. Ye, M. Wang, L. Yuan, H. Yao, X. Jiao, K. Liu, L. Sun, W. Dai, Y. Ling, Y. Wu, S. Chen, Y. Zhang, D. Shi, X. Duan, X. Zhong, X. He, W. Zhai, Y. Zang
Journal: Annals of Oncology (2024)
253P Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant chemotherapy and surgical resection
Authors: S. Kawahara, T. Aoyama, M. Murakawa, R. Kanemoto, N. Matsushita, I. Hashimoto, Y. Maezawa, M. Kamiya, S. Kobayashi, M. Ueno, N. Yamamoto, T. Oshima, N. Yukawa, A. Saito, S. Morinaga
Journal: Annals of Oncology (2024)
156P Efficacy of ipilimumab plus nivolumab therapy in patients having hepatocellular carcinoma with main portal vein invasion (Vp4): Multicenter real-world study
Authors: J.S. Kim, B. Kang, C. An, Y. Kang, I. Hwan Kim, H. Kim, C. Kim, H.J. Chon
Journal: Annals of Oncology (2024)
359P CD13 as a potential membrane marker in PSMA-negative prostate cancer and first-in-human study of [18F]AlF-CD13-L1 PET/CT imaging
Authors: W. Tang, M. Zhou, C. Lu, L. Qi, Y. Zhang, Y. Tang, X. Gao, S. Hu, Y. Cai
Journal: Annals of Oncology (2024)
272MO PUNCH01: Interim results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)
Authors: Z. Wang, B. Huang, C. Luo, Y. Wu, J. Lei, L. Chen, J. Chen
Journal: Annals of Oncology (2024)
73MO Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C–mutated metastatic colorectal cancer (mCRC): Regional analysis of safety and efficacy from CodeBreaK 101
Authors: T. Masuishi, K. Yamaguchi, J.C. Ruffinelli Rodriguez, E. Corral de la Fuente, Y. Kuboki, C. Cremolini, I. Victoria Ruiz, M.E. Elez Fernandez, J.H. Strickler, M. Furqan, B. Bashir, C. Nduka, J. Hippenmeyer, E. Chan, C. Xia, S. Siena
Journal: Annals of Oncology (2024)
135P Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC)
Authors: D-Y. Oh, A.R. He, S. Qin, L-T. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasanvimon, R.E. Zaucha, A. Avallone, J.E. Cundom, A. Kuzko, J. Wang, I. Xynos, J.W. Valle
Journal: Annals of Oncology (2024)
209P Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: A phase II trial
Authors: J-H. Zhong, Z. Deng, L-N. Qi, Z-S. Chen, Z-M. Zhang, B. Xiang, L. Ma
Journal: Annals of Oncology (2024)
182P Real-world treatment (Tx) patterns in patients (pts) with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (HER2+ aGC/GEJC) in East Asia (HER2+ GASTA)
Authors: D-Y. Oh, W. Yeo, J-S. Chen, Y. Ba, W.W.L. Chan, M-J. Chen, Y.H. Chen, K. Gu, Y-P. Hung, J.G. Kim, J. Lee, X. Liang, S. Luo, S.Y. Rha, Y. Yuan, T. Kim, M. Yanagida, R. Sato, R-H. Xu
Journal: Annals of Oncology (2024)
276MO Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: A retrospective cohort study
Authors: C-T. Wu, L. Young, A. Lee, M-Y. Ku, Y-C. Hsieh, H-W. Lin, K-L. Lin, K-P. Chou, M. Kearney, L-N. Chien
Journal: Annals of Oncology (2024)
141P Predictive MINT pathological risk score for adjuvant chemotherapy in resected cholangiocarcinoma: A propensity score matched multicenter study in Thailand
Authors: K. Jeerapradit, C. Sookthon, K. Sriudomporn, S. Chansitthichok, W. Ouransatien, W. Suragul, S. Boonpob, P. Sarkhampee, N. Ngamphaiboon, J. Juengsamarn
Journal: Annals of Oncology (2024)
284P Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in patients with metastatic renal cell carcinoma with high burden disease
Authors: O. Stativko, I. Pokataev, M. Fedyanin, D.A. Kravchuk, I. Andreiashkina, N. Polshina, M.V. Volkonskiy, A. Bystrov, N. Salpagarov, T. Antonova, L. Zhukova, M.I. Volkova, D. Stroyakovskiy, V.N. Galkin
Journal: Annals of Oncology (2024)
145P Efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Impact of hepatitis B virus (HBV) infection
Authors: T. Yau, S.L. Chan, R.K. Kelley, R.S. Finn, C. Yoo, J. Furuse, Z. Ren, H.J. Klumpen, M. Ozaka, U. Pelzer, C. Arslan, J.O. Park, J. Edeline, J.W. Valle, M. Ueno, A. Vogel, L. Starkopf, U. Malhotra, A.B. Siegel, S. Qin
Journal: Annals of Oncology (2024)
301P Effectiveness and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: A preliminary report of real-world data from a single institution in Japan
Authors: Y. Yasuda, T. Urasaki, R. Oki, K. Takemura, Y. Yoneoka, R. Fujiwara, T. Oguchi, N. Numao, J. Yonese, T. Yuasa
Journal: Annals of Oncology (2024)
136P Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: A single-center, single-arm, phase II study
Authors: Y. Zhao, L. Wang, A. Mao, T. Zhang, Q. Pan, L. Wang, Y. Wang, Z. Lin, N. Zhang, J. Zhou, M. Wang, Y. Zhang, Y. Feng, Z. Ding, Y. Wang, Y. Li, Z. Wu
Journal: Annals of Oncology (2024)
346P High genomic risk is associated with clinically significant prostate cancer (csPCa) recurrences following focal therapy (FT)
Authors: B.H. Hong, K.J. Tay, E. Ong, K.M. Tan, Y.G. Tan, Y.M. Law, N.T. Ngo, P.H. Tan, J.S.P. Yuen, H.S.S. Ho, K. Chen, J. Peng, J. Tuan, R. Kanesvaran, Y. Liu, J.A. Proudfoot, E. Davicioni, L.Y. Khor, M.L.K. Chua
Journal: Annals of Oncology (2024)
214P Updated results from phase II study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced hepatocellular carcinoma (HCC)
Authors: H. Zhang, W. Lu, Y. Fu, J. Li, J. Wang, Z. Chen, S. Ding, S. Chen, J. Huang, J. Zhai, None X. li, N. Yang
Journal: Annals of Oncology (2024)
311P The value of blood oxygenation level-dependent (BOLD) MR in differentiation of fumarate hydratase-deficient renal cell carcinoma and high-grade clear cell renal cell carcinoma
Authors: F. Zhao, C. He, Y. Chen, H. Xu, H. Liu, N. Xu, G. Sun, J. Yao, H. Zeng
Journal: Annals of Oncology (2024)